According to the multivariate Cox regression analysis (adjusted for tumor stage, lymph node stage, chemotherapy, and molecular subtype), CCL5 positivity remained an independent prognostic marker for OS in the following subgroups: tumor stage pT3 + 4 (RR = 1.70; p = 0.010) and no chemotherapy (RR = 1.83; p = 0.004), and it was an independent prognostic marker for DSS in the following subgroups: tumor stage pT3 + 4 (RR = 2.31; p < 0.001) and no chemotherapy (RR = 2.36; p < 0.001). This evidence concerns the gene CCL5 and neoplasm.